- Home
- BIIB vs MAA Comparison
BIIB vs MAA Comparison
Compare BIIB & MAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- MAA
- Stock Information
- Founded
- BIIB 1978
- MAA 1977
- Country
- BIIB United States
- MAA United States
- Employees
- BIIB N/A
- MAA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- MAA Real Estate Investment Trusts
- Sector
- BIIB Health Care
- MAA Real Estate
- Exchange
- BIIB Nasdaq
- MAA Nasdaq
- Market Cap
- BIIB 19.9B
- MAA 19.0B
- IPO Year
- BIIB 1991
- MAA 1994
- Fundamental
- Price
- BIIB $125.59
- MAA $163.27
- Analyst Decision
- BIIB Buy
- MAA Buy
- Analyst Count
- BIIB 27
- MAA 20
- Target Price
- BIIB $201.26
- MAA $175.70
- AVG Volume (30 Days)
- BIIB 1.6M
- MAA 731.3K
- Earning Date
- BIIB 05-01-2025
- MAA 04-30-2025
- Dividend Yield
- BIIB N/A
- MAA 3.71%
- EPS Growth
- BIIB 26.39
- MAA 0.75
- EPS
- BIIB 10.12
- MAA 4.81
- Revenue
- BIIB $9,816,400,000.00
- MAA $2,196,688,000.00
- Revenue This Year
- BIIB N/A
- MAA $2.51
- Revenue Next Year
- BIIB N/A
- MAA $3.87
- P/E Ratio
- BIIB $12.43
- MAA $33.95
- Revenue Growth
- BIIB 1.59
- MAA 1.55
- 52 Week Low
- BIIB $110.04
- MAA $126.77
- 52 Week High
- BIIB $238.00
- MAA $173.38
- Technical
- Relative Strength Index (RSI)
- BIIB 55.21
- MAA 53.76
- Support Level
- BIIB $119.18
- MAA $157.52
- Resistance Level
- BIIB $124.82
- MAA $164.81
- Average True Range (ATR)
- BIIB 3.81
- MAA 3.56
- MACD
- BIIB 1.21
- MAA -0.06
- Stochastic Oscillator
- BIIB 98.29
- MAA 58.45
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About MAA Mid-America Apartment Communities Inc.
Mid-America Apartment Communities Inc or MAA, is a real estate investment trust engaged in the acquisition, operation, and development of multifamily apartment communities located in the southeastern and southwestern United States. The company operates two reportable segments; Same Store includes communities that the Company has owned and have been stabilized for at least a full 12 months as of the first day of the calendar year and Non-Same Store and Other includes recently acquired communities, communities being developed or in lease-up, communities that have been disposed of or identified for disposition, communities that have experienced a casualty loss and stabilized communities that do not meet the requirements to be Same Store communities.